The current regulatory framework leaves 503A pharmacies largely untracked, as they fall outside the mandatory reporting requirements imposed on major drug manufacturers and 503B outsourcing facilities. Without a centralized system, incidents of patient harm frequently remain isolated within a single state, preventing regulators from identifying broader safety trends. Executive director Lemrey “Al” Carter emphasized that regulators cannot mitigate risks they cannot see, noting that a unified database will allow a single reported harm to trigger proactive protections for patients nationwide.
In section Releases
NABP to Launch National Clearinghouse for Compounded Drug Safety
When a patient suffers harm from a compounded medication, that data often vanishes into a regulatory blind spot. To close this gap, the National Association of Boards of Pharmacy is building a national clearinghouse designed to capture adverse event reports and bridge the communication divide between state boards and the FDA.
This initiative arrives as the compounding industry faces pressure from a surge in GLP-1 medications, a shift that has outpaced existing oversight models. Beyond the clearinghouse, the Association plans to establish model standards for verifying bulk drug substances and create formal referral pathways between pharmacy boards, medical boards, and state attorneys general. In the coming months, the NABP will convene with the FDA and industry stakeholders to finalize the design and governance of the new reporting infrastructure.
Comments (0)
No comments yet. Be the first!